Gastric Cancer Therapeutics Market: Business Planning Research, Reviews & Comparison of Alternatives
Gastric cancer, also
known as stomach cancer, is a type of cancer that develops within the
inside layer of the stomach. Symptoms may include upper abdominal
pain, yellowing of the skin, heartburn, sudden weight loss, blood in
the stool, loss of appetite, and nausea, among others. This type of
cancer may multiply to unaffected parts of the body mainly to the
lungs, liver, the lining of the abdomen, lymph nodes, and bones. The
key cause of gastric cancer is contagion by Helicobacter pylori. This
accounts for around 60% of the gastric cancer cases. Some types of H.
pylori comprise larger risks than the others. Some of the other
causes include smoking and eating pickled vegetables. Around 1 in 10
cases of gastric cancer are inherited and 1% to 3% of the cases are
due to hereditary syndromes such as hereditary gastric cancer. Most
cases of gastric cancers are gastric carcinomas.
Download
the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/194
According to World
Cancer Research Fund International, 952,000 new cases of gastric
cancer were diagnosed in 2012. Gastric cancer was the fifth-most
common type of cancer in the world. This epidemic has forced
researchers, doctors, and governments to adopt various therapeutic
treatments related to gastric cancer. An increase in investment by
the companies and regulations by the government encouraging research
on the same has provided significant momentum to the growth of the
gastric cancer therapeutics market. This trend is likely to persist
throughout the forecast period, since the number of cases of gastric
cancer around the globe is rising at an alarming rate.
Gastric
cancer therapeutics market taxonomy
On the basis of type
of treatment, the global market is classified into:
Surgery, Targeted
drugs therapy, Chemotherapy, Radiation
therapy, Others
According to
National Cancer Institute, there were a projected 79,843 individuals
with stomach cancer in the U.S. alone, in 2013. According to the same
report, gastric cancer represented a whopping 1.6% of the new cancer
cases reported in the U.S. According to the National Cancer
Institute, an estimated 26,370 new cases of the disease were
reported, leading to 10,730 deaths in the U.S. in 2016. Rising
incidence of stomach cancer in the U.S., positions it as a high
growth market for gastric cancer therapeutics.
Increasing
prevalence of the disease in the Asia to drive growth of overall
gastric cancer therapeutics market
Survival rate for
stomach cancer is greatly dependent upon the stage or phase of the
disease during diagnosis. The earlier the stage of the disease
progression, the higher is the survival rate. In Asia Pacific, the
majority of the cases are detected at the later stage of the disease
and predominantly among the geriatric population. Growth of the
geriatric population in the region is leading to a proportional
increase in occurrence of gastric cancer. This factor, along with
growing health awareness leading to a rise in demand for early
detection would fuel growth of the gastric cancer therapeutics
industry over the forecast period.
Presently, the
products available in the market constitutes of an extensive variety
of treatment alternatives such as angiogenesis inhibitors, new
chemotherapies and HER2-targeted therapy. However, demand for
therapeutics that can take care of HER2-negative stomach cancer
patients is high. Nevertheless, the gastric cancer market is
experiencing a gradual change from generic treatment regimen to
targeted therapies. This will further enhance the growth of the
global gastric cancer therapeutics market.
Some of the companies operating in the gastric cancer therapeutics
market in the current scenario are Pfizer, Eli Lilly, GlaxoSmithKline
plc, Kuhnil Pharmaceutical/Daiichi Sankyo, BMS, Merck KGaA,
AstraZeneca, Otsuka Holdings Co. Ltd., Sanofi, and F. Hoffmann-La
Roche Ltd. Some of the other companies operating in the market are
Ono Pharmaceutical/Bristol-Myers Squibb, Jiangsu HengRui Medicine,
Gilead Bioscience, Celgene/Taiho, Boston Biomedical, and Merck. Click
To Read More On Gastric
Cancer Therapeutics Market
About
Coherent Market Insights:
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Comments
Post a Comment